Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1

Published:2011-06-12 Issue:10 Volume:52 Page:1980-1990
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Gromicho Marta,Dinis Joana,Magalhães Marta,Fernandes Alexandra R.,Tavares Purificação,Laires António,Rueff José,Rodrigues António Sebastião

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2011.584005

Reference41 articles.

1. Characterization of cancer stem cells in chronic myeloid leukaemia

2. Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia

3. Oncogene addiction: setting the stage for molecularly targeted cancer therapy

4. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

5. Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidrug resistance phenotype and its relation to stem cell characteristics in chronic myeloid leukemia;Gene;2024-01

2. Transporter-Mediated Cellular Distribution of Tyrosine Kinase Inhibitors as a Potential Resistance Mechanism in Chronic Myeloid Leukemia;Pharmaceutics;2023-10-26

3. The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism;Scientific Reports;2023-08-11

4. Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to imatinib mesylate, in Iranian chronic myeloid leukemia patients;Egyptian Journal of Medical Human Genetics;2023-01-03

5. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia;Precision Medicine;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3